William Blair Reiterates Outperform as ABBV-295 Study Delivers 9.79% Weight Loss
AbbVie reported Phase 1 topline results for its long-acting amylin analog ABBV-295, showing mean body weight reductions of 7.75% to 9.79% at week 12 with no serious adverse events. William Blair reiterated its Outperform rating, highlighting AbbVie’s strong amylin-class position and differentiated weight-management profile.
1. Positive Phase 1 Data
On March 9, AbbVie announced topline results from its Phase 1 trial of ABBV-295, a long-acting amylin analog. Weekly dosing produced mean body weight reductions of 7.75% to 9.79% at week 12, with mild gastrointestinal disorders as the most common adverse events and no serious safety concerns.
2. Rating Reaffirmation by William Blair
William Blair reiterated its Outperform rating on AbbVie, citing the company’s strong position in the amylin class and the differentiated profile of ABBV-295 in chronic weight management.
3. Pipeline and Development Outlook
ABBV-295 is being evaluated across doses ranging from 2 mg to 14 mg, positioning AbbVie to compete with other long-acting amylin therapies. The company plans to advance to later-stage trials pending regulatory review of Phase 1 data.
4. Recent Stock Movements
Despite the positive study results, AbbVie shares declined 2.22% to trade between $223.23 and $230.68, with about 4.05 million shares changing hands. The company’s market capitalization stands near $397.9 billion, reflecting active investor interest and volatility following the announcement.